Association between Serum Ceruloplasmin level and Dyslipidemia: Study in Tertiary care Teaching Hospital
Abstract
Introduction: Dyslipidemia is one of the major morbid events preceding CAD all around. The conventional risk factors have failed to predict the risk of coronary events in around 30 – 40% cases; hence an emphasis is being given to search new able risk factors. With this respect the study tried to evaluate the correlation of serum ceruloplasmin levels in dyslipidemic patients. The aim of the study was to study the correlation of serum ceruloplasmin and Dyslipidemia.
Methods: 60 Subjects were screened for dyslipidemia by estimation of serum total cholesterol, triacylglycerol, HDL and LDL and were categorized into cases and controls and serum ceruloplasmin was estimated in all of them.
Results: Serum mean ceruloplasmin level in dyslipidemics was significantly raised as compared to controls. Odds ratio as high as 15.54 shows a positive correlation of serum ceruloplasmin and dyslipidemia. Ceruloplasmin levels are associated with dyslipidemia( especially LDL values) showing ‘positive r values’ and ‘p’ value is significant.
Discussion: Raised serum ceruloplasmin levels in dyslipidemics as compared to normal healthy subjects suggest that dyslipidemics are more prone for rise in ceruloplasmin levels than the healthy subjects supporting our hypothesis that raised serum ceruloplasmin levels could enhance the risk for coronary artery diseases. Raised serum Ceruloplasmin level in association with LDL values in dyslipidemics should be considered as an added risk factor for CAD. Antioxidant supplementation orally to reduce ceruloplasmin levels can be considered as a new approach of treatment in the future.
Downloads
References
2. Kontush A, Chantepie S, Chapman MJ. 2003. Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler. Thromb. Vasc. Biol.2003; 23: 1881–1888. [PubMed]
3. Isselbacher, Braunwald, Wilson, Martin, Fauci, Kasper. Harrison’s Principles of Internal Medicine 17th edition vol 2,Mcgraw Hill, 2006:1425-30.
4. Virgolici B., Mohora M., Radoi V., Lixandru D., Stoian I., Gaman L., Coman A., Greabu M., Manuel-y-Keenoy B. Correlations between dysglycemia, markers of oxidative stress and inflammation in diabetic foot patients, Farmacia, 2011, 59 (2), 216-226.
5. Somani BL, Ambade V. A kinetic method amenable to automation for ceruloplasmin estimation with inexpensive and stable reagents. Clin Biochem. 2007;40:571–4. [PubMed]
6. Myers G. L.,Kimberly M. et al, A reference method laboratory network for cholesterol : a model for standerdisation and improvement of clinical laboratory measurement ., clin . chem., 2000, 46, p (1762~ 1772). [PubMed]
7. Henry J.B., Clinical diagnosis and management of laboratory methods, 18th edition, W.B. Saunders Philadelphia, p (204-211).
8. Miller WG, Myers GL, Sakurabayashi I, Bachmann LM, Laudill SP, Dzerekonski A, Edwards S, Kimberly MM, Korzun WJ, Leary ET, Nakajima K, Nakamura M, Nilson G, Shamburek RD, Vetrovec GW, Warwick GR, Remaley AT, Seven Direct Methods for Measuring HDL and LDL Cholesterol Compared with Ultracentrifugation Reference Measurement Procedures Clinical Chemistry. June 2010; 56( 6): 977-986.
9. Jellinger P, The American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Dyslipidemia and Prevention of Atherogenesis 2002 Amended Version. Endocr Pract. 2000;6(No.2)164-174.
10.Tenenbaum A, Fisman EZ, Motro M, Adler Y. Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins. Cardiovascu Diabetol 2006, 5:20. [PubMed]
11. Genest J, Frohlich J, Fodor G, Mcpherson R, Recommendation for the management of dyslipedemia & the prevention of cardiovascular disease. CMAJ 2003;168(9):921-4. [PubMed]
12. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L Effect of potentially modifiable risk factors associated with Myocardial Infarction in 52 countries: case control study. Lancet. 2004 Sep 11-17;364(9438):937-52.
13. Lusis AJ: Atherosclerosis. Nature 2000 sep 14; 407(6801): 233-241. [PubMed]
14. Bogdana Vîrgolici, Maria Mohora, Laura Găman, Daniela Lixandru B. Manolescu, Anca Coman, Irina Stoian. Relation Between Inflammation And Oxidative Stress Markers In Diabetic Foot Patients. Romanian J. Biophys. 2008, 18(4) 273–282.
15. Ehrenwald E, Chisolm GM, Fox PL. Intact human serum ceruloplasmin oxidatively modifies Low density lipoproteins. J Clin Invest. 1994 April; 93(4): 1493–1501.
OAI - Open Archives Initiative
